Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Leukemia|November 2, 2021
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyThomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.
American Journal of Hematology|September 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAndrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
The New England Journal of Medicine|May 10, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.
Blood|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Leukemia|November 2, 2021
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyThomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.
American Journal of Hematology|September 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAndrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
Pageof 12